Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital.
Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
Ageing causes stem cells to lose their normal structure by increased activity of the protein CDC42. Normalising CDC42 activity can restore structure, order and functionality in those aged stem cells.
The underlying technology was developed over the last 15 years by the two scientific co-founders, Professor Yi Zheng, Co-director of the Cincinnati Children’s Hospital Cancer and Blood Diseases Institute and leader of the Signaling and Drug Discovery Program at the Cincinnati Children’s Research Foundation, and Professor Dr Hartmut Geiger, Director of the Institute of Molecular Medicine at Ulm University in Germany.
“We are really excited that Kizoo’s financial support will allow us to pursue our goal of rejuvenating ageing stem cells, which are so important for blood cell production and the immune system. Our approach has particular potential in treating diseases of the blood system and improving the immune system”, said Dr Jürgen Reess, CEO of Mogling Bio.
